Partial
Mostly Aligned
Patient Risk:
Low
Summary
The excerpted AI claim about serotype coverage/limitation is supported by the provided FDA label sections (1.1–1.4). However, the broader response content includes multiple entries that cannot be verified against the supplied label text (e.g., product-label matching/section-number verification and an attempted additional structured output not clearly attributable to the AI response claims), limiting confidence in overall alignment.
Category Scores
Accurate Statements
Prevnar 13 indication/coverage is limited to prevention of invasive pneumococcal disease caused by specific included S. pneumoniae serotypes (as reflected in label sections 1.1–1.3).
Label references: 1.1, 1.2, 1.3
Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine (label limitation in section 1.4).
Label reference: 1.4
Unsupported Statements
“I can’t verify adherence to FDA-approved labeling because the specific product name/label text is not provided. The section numbers (1.1–1.4) may correspond to the indication and coverage limitation, but I cannot confirm they match the actual label for the referenced product without the label.”
In this prompt, the label excerpts for sections 1.1–1.4 are provided; therefore, this statement is not supported by the information actually supplied for those sections.
Contradictions
Important Omissions
The AI’s response does not explicitly state the otitis media limitation details for specific serotypes/absence of efficacy data for other serotypes, even though the provided label excerpt includes those specifics (1.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The supported limitation statement about non-included serotypes is consistent with label guidance. Missing otitis media specificity could affect accuracy but is not directly framed as safety-critical in the provided excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Contains an unsupported statement claiming inability to verify label adherence despite relevant label excerpts (1.1–1.4) being provided in the prompt.
Suggested Improvement
Remove the unsupported verification uncertainty and, if relevant to the claim, include the otitis media serotype-specific efficacy/limitations details contained in section 1.1.